Recombinant Human ANGPTL3, His-tagged

• Cat.No.: ANGPTL3-101H
• Product Overview: Total 223 AA. MW: 26 kDa (calculated). N-Terminal His-tag, 16 extra AA (highlighted).

Specification

• Cat. No.: ANGPTL3-101H
• Description: The protein encoded by this gene is a member of the angiopoietin-like family of secreted factors. It is predominantly expressed in the liver, and has the characteristic structure of angiopoietins, consisting of a signal peptide, N-terminal coiled-coil domain and the C-terminal fibrinogen (FBN)-like domain.
• Source: E. coli
• Species: Human
• Form: Filtered (0.4 μm) and lyophilized in 0.5 mg/mL in 0.05M Acetate buffer pH 4.
• Purity: >95%
• Research topic: Energy metabolism and body weight regulation.
• Reconstitution: Add deionized water to prepare a working stock solution of approximately 0.5 mg/mL and let the lyophilized pellet dissolve completely. Product is not sterile! Please filter the product by an appropriate sterile filter before using it in the cell culture.
• Applications: Biologically active protein; ELISA; Western blotting
• Quality Control Test: BCA to determine quantity of the protein; SDS PAGE to determine purity of the protein
• Sequences of amino acids: MRGSHHHHHH GMASHMSRID QDNSSFDSLS PEPKSRFAML DDVKILANGL LQLGHGLKDF VHKTKGQIND IFQKLNIFDQ SFYDLSLQTS EIKEEEKELR RTTYKLQVKN EEVKNMSLEL NSKLESLLEE KILLQQKVKY LEEQLTNLIQ NQPETPEHPE VTSLKTFVEK QDNSIKDLLQ TVEDQYKQLN QQHSQIKEIE NQLRRTSIQE PTEISLSSKP RAP
• Storage: Store lyophilized protein at -20°C. Lyophilized protein remains stable until the expiry date when stored at -20°C. Aliquot reconstituted protein to avoid repeated freezing/thawing cycles and store at -80°C for long term storage. Reconstituted protein can be stored at 4°C for a limited period of time; it does not show any change after one week at 4°C.
• Pathways: Integrins in angiogenesis

Gene Information

• Gene Name: ANGPTL3 angiopoietin-like 3 [ Homo sapiens ]
• Official Symbol: ANGPTL3
• Synonyms: ANGPTL3; angiopoietin-related protein 3; FHBL2; ANGPT5; ANG-5; angiopoietin 5; OTTHUMP00000010719; UNQ153/PRO179
• Gene ID: 27329
• mRNA Refseq: NM_014495
• Protein Refseq: NP_055310
• MIM: 604774
• UniProt ID: Q9Y5C1
• Chromosome Location: 1p31.1-p22.3
• Function: cell surface binding; enzyme inhibitor activity; growth factor activity; integrin binding; phospholipase inhibitor activity; protein binding

Reviews

04/04/2021

One of the standout advantages offered by the manufacturer is their excellent technical support.

10/10/2018

The ANGPTL3 protein is of exceptional quality, meeting all my experimental requirements with precision and reliability.

09/29/2018

They continuously stay up-to-date with the latest scientific advancements and customer feedback, allowing them to refine the ANGPTL3 protein based on emerging trends.

09/27/2017

This exceptional level of support enables me to overcome challenges efficiently and progress smoothly with my research.

05/05/2016

They provide comprehensive assistance, ensuring that any queries or concerns I have regarding the ANGPTL3 protein are promptly addressed.

Q&As

Are there any ongoing research studies related to ANGPTL3?

Yes, research on ANGPTL3 is ongoing. Studies are being conducted to better understand its mechanisms of action, explore its potential therapeutic applications, and assess its long-term effects.

Is ANGPTL3 genetic testing available?

Yes, genetic testing for ANGPTL3 mutations can help identify individuals who may benefit from ANGPTL3-targeted therapies, although it is not currently a routine clinical practice and is typically reserved for research or specialized testing purposes.

Are there any side effects associated with ANGPTL3-targeted therapies?

The side effects of ANGPTL3-targeted therapies are still being investigated. However, some studies have reported mild side effects, such as injection site reactions, headache, and muscle pain. It is important to consult with a healthcare professional for more specific information on the potential side effects of ANGPTL3-targeted therapies.

Is ANGPTL3 deficiency a rare condition?

Yes, ANGPTL3 deficiency is a relatively rare condition. It is usually caused by specific genetic mutations that impair ANGPTL3 production or function. The prevalence of ANGPTL3 deficiency in the general population is estimated to be very low.

Can ANGPTL3 therapies be used in combination with other cholesterol-lowering medications?

Combination therapy with ANGPTL3 inhibitors and other cholesterol-lowering medications, such as statins, has shown potential for achieving more significant reductions in LDL cholesterol and triglyceride levels. However, the safety and efficacy of combining ANGPTL3 therapies with other medications may vary, and it is important to consult with a healthcare professional for personalized treatment recommendations.

Can ANGPTL3-targeted therapies be used as a preventive measure for cardiovascular disease?

ANGPTL3-targeted therapies have the potential to reduce the risk of cardiovascular disease by lowering LDL cholesterol and triglyceride levels. However, their exact role as a preventive measure is still being investigated, and more research is needed to determine their long-term efficacy and benefits in preventing heart disease.

Have ANGPTL3-targeted therapies shown promising results in clinical trials?

Yes, clinical trials investigating ANGPTL3-targeted therapies have shown promising results in reducing LDL cholesterol and triglyceride levels in individuals with a genetic predisposition to high lipid levels.

Can ANGPTL3 gene variations affect an individual's response to lipid-lowering drugs?

Genetic variations in the ANGPTL3 gene may potentially affect an individual's response to lipid-lowering drugs. Certain variations may influence how an individual's body metabolizes and responds to these medications, leading to differences in their effectiveness. However, more research is needed to fully understand the impact of ANGPTL3 gene variations on drug response.

Are there any potential therapies targeting ANGPTL3?

ANGPTL3 inhibitors, such as monoclonal antibodies or antisense oligonucleotides, are being explored as potential therapeutic approaches to reduce ANGPTL3 activity and lower lipid levels.

Can ANGPTL3-targeted therapies be used in combination with other cholesterol-lowering medications?

The potential interactions between ANGPTL3-targeted therapies and other cholesterol-lowering medications are still being studied. Combining these therapies with other medications may show additive or synergistic effects, but further research is needed to determine their compatibility and safety.

What are the potential benefits of ANGPTL3-targeted therapies?

ANGPTL3-targeted therapies have the potential to lower LDL cholesterol and triglyceride levels, which are both risk factors for cardiovascular disease. By reducing ANGPTL3 activity, these therapies may help reduce the risk of heart disease and related complications.

How is ANGPTL3 related to cardiovascular disease?

ANGPTL3 has been associated with an increased risk of cardiovascular disease. Elevated levels of ANGPTL3 have been found to be a risk factor for atherosclerosis, coronary artery disease, and other cardiovascular events. Inhibiting ANGPTL3 activity has shown promise in reducing cardiovascular risk factors, such as LDL cholesterol and triglyceride levels.

Are there any clinical trials investigating ANGPTL3 therapies?

There have been and continue to be clinical trials investigating ANGPTL3 therapies. These trials aim to evaluate the safety and efficacy of various drug candidates targeting ANGPTL3 in treating hyperlipidemia and related disorders.

Are there any genetic mutations related to ANGPTL3?

Yes, there have been identified genetic mutations in the ANGPTL3 gene that can lead to significantly reduced or absent ANGPTL3 protein production. These mutations have been associated with lower levels of LDL cholesterol, triglycerides, and higher levels of high-density lipoprotein (HDL) cholesterol, resulting in the condition called familial hypobetalipoproteinemia.

Can ANGPTL3 levels be modified through lifestyle changes?

While lifestyle changes alone may not directly impact ANGPTL3 levels, they can influence lipid and glucose metabolism, which in turn can affect ANGPTL3 regulation. Healthy lifestyle choices, including regular exercise, a balanced diet, weight management, and avoidance of smoking, can contribute to improved lipid and glucose metabolism, potentially leading to healthier ANGPTL3 levels.

Are there any side effects associated with ANGPTL3-targeted therapies?

Clinical trials have shown that ANGPTL3-targeted therapies have generally been well-tolerated, with few reported side effects. However, long-term safety data are still limited, and further research is needed to understand any potential side effects.

Can ANGPTL3 levels be influenced by lifestyle or diet?

Yes, studies have shown that lifestyle factors such as diet and exercise can influence ANGPTL3 levels. A high-sugar diet and sedentary behavior have been associated with higher ANGPTL3 levels, while a healthy, balanced diet and regular physical activity may help normalize its levels.

Are there any specific populations that may benefit more from ANGPTL3-targeted therapies?

ANGPTL3-targeted therapies may be particularly beneficial for individuals with genetically determined high cholesterol levels, such as those with familial hypercholesterolemia. They may also be helpful for individuals who do not respond well to or cannot tolerate traditional cholesterol-lowering medications. However, further research is needed to identify specific populations that may benefit the most from these therapies.

Are there any drug therapies targeting ANGPTL3?

Yes, there are drug therapies being developed that target ANGPTL3. These therapeutic approaches aim to inhibit the activity of ANGPTL3 to reduce LDL cholesterol and triglyceride levels in individuals with hyperlipidemia or other related conditions.

Are ANGPTL3-targeted therapies approved for widespread use?

No, ANGPTL3-targeted therapies are still under development and have not yet received regulatory approval for widespread use. Further research is needed to determine their long-term effectiveness and safety profile.

Are there any dietary or lifestyle changes that can naturally lower ANGPTL3 levels?

While there is no specific dietary or lifestyle change that can directly lower ANGPTL3 levels, adopting a healthy lifestyle can indirectly help maintain balanced lipid metabolism. Regular physical activity, a balanced diet rich in fruits, vegetables, and whole grains, and avoiding excessive consumption of added sugars and unhealthy fats can benefit overall heart health and lipid profile, including LDL cholesterol and triglyceride levels.

Can ANGPTL3 deficiency be beneficial?

Yes, ANGPTL3 deficiency has been associated with certain health benefits. Individuals with genetic mutations causing low or absent ANGPTL3 production have been found to have reduced risk of cardiovascular disease, lower LDL cholesterol, lower triglycerides, and higher HDL cholesterol levels. However, further research is needed to fully understand the potential benefits and any potential side effects of ANGPTL3 deficiency.

Besides lipid metabolism, does ANGPTL3 have any other functions?

ANGPTL3 has been found to have additional roles beyond lipid metabolism. It has been implicated in angiogenesis (the formation of new blood vessels) and in regulating glucose metabolism.

What happens if ANGPTL3 levels are elevated?

Elevated levels of ANGPTL3 can result in decreased LPL activity, leading to increased levels of triglycerides and LDL cholesterol in the bloodstream.

Are there any genetic mutations associated with ANGPTL3?

Yes, genetic mutations that cause ANGPTL3 deficiency or loss-of-function have been associated with lower levels of LDL cholesterol and triglycerides.

Are there any ANGPTL3-targeted therapies currently approved for use?

Yes, there are approved ANGPTL3-targeted therapies available. One example is evinacumab, which was approved by the U.S. Food and Drug Administration (FDA) in February 2021 for the treatment of homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder characterized by extremely high cholesterol levels. Evinacumab is an antibody that targets and inhibits ANGPTL3, leading to decreased LDL cholesterol levels.

What are the limitations or challenges associated with ANGPTL3-targeted therapies?

One limitation of ANGPTL3-targeted therapies is the high cost, as they are currently expensive medications. This can limit their accessibility and affordability for some individuals. Additionally, long-term safety data are still limited, and potential side effects or interactions with other medications need to be further explored.